Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 0.83% is 27% above its 2-year average of 0.66%, around the middle of its 2-year range (0.12%–1.54%).
As of the fiscal period ended Tuesday, June 30, 2026. 73.53% above its 12-month average of 0.48%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.83%.
DEBT TO ASSETS RATIO
0.83%
DEBT TO ASSETS RATIO AVG TTM
0.48%
DEBT TO ASSETS RATIO AVG 3Y
N/A
DEBT TO ASSETS RATIO AVG 5Y
N/A
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+73.53%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.09%
median of 866 covered companies
CURRENT VS SECTOR MEDIAN
+823.43%
vs the sector median at left
Aardvark Therapeutics, Inc. Common Stock
Market Cap
$110.41M
Debt to Assets Ratio
0.83%
TTM Avg
0.48%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$110.12M
Debt to Assets Ratio
0.65%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$112.37M
Debt to Assets Ratio
0.21%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$112.53M
Debt to Assets Ratio
0.09%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$108.18M
Debt to Assets Ratio
0.07%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$112.81M
Debt to Assets Ratio
0.01%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$107.28M
Debt to Assets Ratio
0.70%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$107.09M
Debt to Assets Ratio
0.03%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $110.41M | 0.83% | 0.48% | N/A | N/A |
| Apyx Medical Corporation (APYX)vs › | $110.12M | 0.65% | N/A | N/A | N/A |
| Foghorn Therapeutics Inc. (FHTX)vs › | $112.37M | 0.21% | N/A | N/A | N/A |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $112.53M | 0.09% | N/A | N/A | N/A |
| Cumberland Pharmaceuticals Inc. (CPIX)vs › | $108.18M | 0.07% | N/A | N/A | N/A |
| Unicycive Therapeutics, Inc. (UNCY)vs › | $112.81M | 0.01% | N/A | N/A | N/A |
| Immunic, Inc. (IMUX)vs › | $107.35M | 0.00% | N/A | N/A | N/A |
| Outlook Therapeutics, Inc. (OTLK)vs › | $107.28M | 0.70% | N/A | N/A | N/A |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP)vs › | $107.09M | 0.03% | N/A | N/A | N/A |
| Caribou Biosciences, Inc. (CRBU)vs › | $114.06M | 0.19% | N/A | N/A | N/A |
Debt/Assets
0.8%
Debt/Equity
0.01
Current Ratio
12.63
Interest Coverage
N/A
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 0.83% |
| 2026-03-31 | 0.34% |
| 2025-12-31 | 0.38% |
| 2025-09-30 | 0.41% |
| 2025-06-30 | 0.44% |
| 2025-03-31 | 0.46% |
| 2024-12-31 | 1.01% |
| 2024-09-30 | 1.04% |
| 2024-06-30 | 0.12% |
| 2023-12-31 | 1.54% |
